arrow
C

Carolina Gabri Nicoletti

University of Rome Tor Vergata
H指数:19
被引数:1,370

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic value of the kappa free light chain index in multiple sclerosis under the 2024 CSF positivity criterion: a multicentre study in oligoclonal band-negative patients

2024年脑脊液阳性标准下κ游离轻链指数在多发性硬化中的诊断价值:一项在寡克隆带阴性患者中的多中心研究

2026-11-080
OA
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian study

真实世界中多发性硬化患者使用克拉屈滨片的经验:一项多中心意大利研究的有效性数据

2025-12-260
OA
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy

怀孕期间暴露于富马酸二甲酯的多发性硬化症妇女的意大利多中心队列的母婴结局

2024-09-120
PRE
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study

Ocrelizumab在阿仑单抗治疗后疾病活动持续存在的MS患者中: 一项多中心意大利研究

2024-08-140
PRE
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

整个怀孕期间暴露于那他珠单抗: 在意大利多发性硬化症女性队列中的有效性和安全性

2022-09-3015
PRE
Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment

JC多瘤病毒病毒尿、病毒血症、血清状态及microRNA表达在多发性硬化免疫抑制治疗中的诊断价值

2022-01-115
OAAI
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment

Ocrelizumab治疗1年期间多发性硬化患者进行性多灶性白质脑病的风险评估

2021-08-256
OAAI
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
2021-04-1514
PREAI
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation
2021-02-1021
PREAI